



Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

February 19, 2025

PHILADELPHIA, Feb. 19, 2025 /PRNewswire/ -- [Carisma Therapeutics Inc.](#) (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Michael Klichinsky, PharmD, PhD, Co-founder and Chief Scientific Officer, will participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25 at 10:30 am ET.

—
An audio webcast of the event will be available on the Company's [Investor Events](#) section of the Investor Relations webpage and will be archived for a limited time following the event.

About Carisma

Carisma Therapeutics is a biopharmaceutical Company pioneering macrophage engineering to develop groundbreaking therapies for fibrosis, cancer, and other diseases. With a strong commitment to patient-centric innovation, Carisma aims to deliver scalable, next-generation solutions that transform treatment paradigms. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.Carismatx.com.

Investors:

Shveta Dighe
investors@carismatx.com

Media Contact:

Julia Stern
(763) 350-5223
jstern@realchemistry.com

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/carisma-therapeutics-to-participate-in-hc-wainwright-3rd-annual-cell-therapy-virtual-conference-302379463.html>

SOURCE Carisma Therapeutics Inc.